Evidence map›Paper›PMID 29112740›Full record

ArticleRheumatology (Oxford, England)2018

Evaluation of damage in giant cell arteritis.

Tanaz A Kermani, Antoine G Sreih, David Cuthbertson, Simon Carette, Gary S Hoffman, Nader A Khalidi, Curry L Koening, Carol A Langford, Carol A McAlear, Paul A Monach and 7 more

Registry-linked trialOpen access · bronzeAbstract readEvaluation StudyMulticenter Study
In one paragraph

Article in Rheumatology (Oxford, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04204876 (Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04204876 completednot on this mapstarted 2020, after this paper: background citation

Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course

TypeobservationalSponsorUniversity Hospital, Basel, SwitzerlandRan2020 to 2023Enrolled40ConditionsGiant Cell Arteritis, Large Vessel Giant Cell ArteriitisArmsMagnet Resonance Imaging (MRI), PET/CT analysis
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026
    Review
  4. Article
  5. Assessment of damage in Takayasu's arteritis.Rheumatology (Oxford, England) · 2025
    Observational
  6. Article
  7. Review
  8. Looking ahead: giant-cell arteritis in 10 years time.Therapeutic advances in musculoskeletal disease · 2022
    Review
  9. Review
  10. Observational
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Osteoporosis in Rheumatic Diseases.International journal of molecular sciences · 2019
    Review
  17. Observational
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 2 countries.

Tanaz A KermaniDivision of Rheumatology, University of California Los Angeles, Los Angeles, CA.
Antoine G SreihDivision of Rheumatology, University of Pennsylvania, Philadelphia, PA.
David CuthbertsonDepartment of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, USA.
Simon CaretteDivision of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.
Gary S HoffmanDepartment of Rheumatic and Immunologic Diseases, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, USA.
Nader A KhalidiDivision of Rheumatology, St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Curry L KoeningDivision of Rheumatology, University of Utah, Salt Lake City, UT.
Carol A LangfordDepartment of Rheumatic and Immunologic Diseases, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, USA.
Carol A McAlearDivision of Rheumatology, University of Pennsylvania, Philadelphia, PA.
Paul A MonachSection of Rheumatology, Boston University School of Medicine, Boston, MA.
Larry MorelandDivision of Rheumatology, University of Pittsburgh, Pittsburgh, PA.
Christian PagnouxDivision of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.
Philip SeoDivision of Rheumatology, Johns Hopkins University, Baltimore, MD.
Kenneth J WarringtonDivision of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN.
Steven R YtterbergDivision of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN.
Peter A MerkelDivision of Rheumatology and Department of Biostatistics and Clinical Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
Vasculitis Clinical Research Consortium
University of Pennsylvania · USCleveland Clinic Lerner College of Medicine · USMayo Clinic in Arizona · USMount Sinai Hospital · CABoston University · USJohns Hopkins University · USSt. Joseph’s Healthcare Hamilton · CAUniversity of California, Los Angeles · USUniversity of Pittsburgh · USUniversity of South Florida · USUniversity of Utah · US

Funding

VCRC-VF FellowshipU54AR057319 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI MERKEL, PETER A · 2009 to 2020
$12.5M
VASCULITIS CLINICAL RESEARCH NETWORK (VCRN): RARE DISEASEU54RR019497 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MERKEL, PETER A · 2003 to 2008
$6.1M
NCRR NIH HHS U54 RR019497NIAMS NIH HHS U54 AR057319
6 · The paper itself

Abstract

Objectives: To evaluate damage and variables associated with damage in GCA. Methods: Patients with GCA enrolled in a prospective, multicentre, longitudinal study were included. Per-protocol assessments were made with the Vasculitis Damage Index and the Large-Vessel Vasculitis Index of Damage. Results: The study included 204 patients: 156 women (76%), mean age at diagnosis 71.3 years (s.d. 8.3), mean follow-up of 3.5 years (s.d. 1.9). One or more damage item was present in 54% at baseline and 79% at the last follow-up on the Vasculitis Damage Index, and 60% at baseline and 82% at the last follow-up on the Large-Vessel Vasculitis Index of Damage. The most frequently observed damage items were large-artery complications (29% cohort) and ocular (22%). Among 117 patients with new damage, most new items were ocular (63 patients), cardiac/vascular (48) and musculoskeletal (34). Of these, treatment-associated items were frequently observed, including cataracts (46 patients), osteoporosis (22) and weight gain (22). Disease-associated new damage included ischaemic optic neuropathy (3 patients), limb claudication (13), arterial occlusions (10) and damage requiring vascular intervention (10). In univariate analysis, the risk of damage increased 22% for every additional year of disease duration [odds ratio (OR) 1.22 (95% CI 1.04, 1.45)]. In 94 patients enrolled within ⩽90 days of diagnosis of GCA, the risk of new damage at the last follow-up decreased 30% for each additional relapse [OR 0.70 (95% CI 0.51, 0.97)]. Conclusions: Large-artery complications and ocular manifestations are the most commonly occurring items of damage in GCA. Most new damage is associated with treatment. These findings emphasize the cumulative burden of disease in GCA.

Indexed as

Severity of Illness IndexAgedEye DiseasesFemaleFollow-Up StudiesGiant Cell ArteritisHumansIntermittent ClaudicationLongitudinal StudiesMaleMiddle AgedOdds RatioProspective StudiesRecurrenceRisk FactorsTime Factorsdamagegiant cell arteritislarge-artery manifestationslarge-vessel vasculitisvasculitis

Identifiers

PMID29112740
PMCPMC5850105
OpenAlexW2794177437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.